Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Lluch

Showing results (61-70 of 186) with videos related to

Pageof 19
Sort By:
Breast (Edinburgh, Scotland)|August 6, 2011
Removal of primary tumor improves survival in metastatic breast cancer. Does timing of surgery influence outcomes?Jose Alejandro Pérez-Fidalgo, Paola Pimentel, Antonio Caballero, et al.
International Journal of Molecular Sciences|August 7, 2021
Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical PerspectiveCristina Hernando, Belén Ortega-Morillo, Marta Tapia, et al.
Breast Cancer Research and Treatment|September 16, 2016
Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancerJuan Miguel Cejalvo, J Alejandro Pérez-Fidalgo, Gloria Ribas, et al.
Cancer Treatment Reviews|June 15, 2007
Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trialsLaura G Estévez, Montserrat Muñoz, Isabel Alvarez, et al.
Breast (Edinburgh, Scotland)|November 29, 2007
Time-to-progression in breast cancer: a stratification model for clinical trialsJuan de la Haba-Rodríguez, Enrique Aranda, Antonio Llombart, et al.
BMC Cancer|March 30, 2013
Genetic variants in PARP1 (rs3219090) and IRF4 (rs12203592) genes associated with melanoma susceptibility in a Spanish populationMaria Peña-Chilet, Maite Blanquer-Maceiras, Maider Ibarrola-Villava, et al.
American Journal of Cancer Research|December 2, 2016
Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell linesSandra Zazo, Paula González-Alonso, Ester Martín-Aparicio, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|March 29, 2013
Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in SpainEmilio Alba, Eva Ciruelos, Rafael López, et al.
ACS Applied Materials & Interfaces|August 7, 2023
Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer TherapyIris Garrido-Cano, Anna Adam-Artigues, Ana Lameirinhas, et al.
Oncotarget|March 2, 2015
PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effectsRaúl Rincón, Ion Cristóbal, Sandra Zazo, et al.
Pageof 19

Showing results (61-70 of 186) with videos related to

Sort By:
Pageof 19
Breast (Edinburgh, Scotland)|August 6, 2011
Removal of primary tumor improves survival in metastatic breast cancer. Does timing of surgery influence outcomes?Jose Alejandro Pérez-Fidalgo, Paola Pimentel, Antonio Caballero, et al.
International Journal of Molecular Sciences|August 7, 2021
Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical PerspectiveCristina Hernando, Belén Ortega-Morillo, Marta Tapia, et al.
Breast Cancer Research and Treatment|September 16, 2016
Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancerJuan Miguel Cejalvo, J Alejandro Pérez-Fidalgo, Gloria Ribas, et al.
Cancer Treatment Reviews|June 15, 2007
Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trialsLaura G Estévez, Montserrat Muñoz, Isabel Alvarez, et al.
Breast (Edinburgh, Scotland)|November 29, 2007
Time-to-progression in breast cancer: a stratification model for clinical trialsJuan de la Haba-Rodríguez, Enrique Aranda, Antonio Llombart, et al.
BMC Cancer|March 30, 2013
Genetic variants in PARP1 (rs3219090) and IRF4 (rs12203592) genes associated with melanoma susceptibility in a Spanish populationMaria Peña-Chilet, Maite Blanquer-Maceiras, Maider Ibarrola-Villava, et al.
American Journal of Cancer Research|December 2, 2016
Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell linesSandra Zazo, Paula González-Alonso, Ester Martín-Aparicio, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|March 29, 2013
Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in SpainEmilio Alba, Eva Ciruelos, Rafael López, et al.
ACS Applied Materials & Interfaces|August 7, 2023
Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer TherapyIris Garrido-Cano, Anna Adam-Artigues, Ana Lameirinhas, et al.
Oncotarget|March 2, 2015
PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effectsRaúl Rincón, Ion Cristóbal, Sandra Zazo, et al.
Pageof 19